SINGAPORE: BioNTech will shutter its vaccine manufacturing plant in Singapore by the end of February next year, the German biotechnology firm said on Thursday (Apr 2), following a “comprehensive review”.
The company has suffered losses in recent years and reported last month a net loss of €1.14 billion (US$1.31 billion) in 2025, compared with a €665 million loss in 2024.
“BioNTech made the strategic decision to close its planned Singapore site by the end of February 2027, as we continue to align capacity with our clinical portfolio and long-term strategic direction,” the COVID-19 vaccine maker told CNA.
“We recognise the significant contributions of our employees affected by these changes and are committed to supporting them through this transition.”
CNA Games
Show More Show Less
The company added that it currently employs 85 people at its Singapore site in Tuas.
BioNTech also told CNA that it is committed to becoming a global immunotherapy powerhouse with multiple approved products.
“While we continue to invest in executing our vision, we remain committed to cost-effective value generation,” said the company.
“We actively manage our whole pipeline and assess all sites across BioNTech, according to key criteria: strategic alignment, operational efficiency, and sustainable value creation.
“We consequently plan to continue to significantly invest in essential areas while optimising capacities in others.”
The impending closure of its Singapore plant comes shortly after BioNTech's two co-founders and leading executives, CEO Ugur Sahin and Chief Medical Officer Oezlem Tuereci, announced on Mar 10 that they will leave the vaccine maker before the end of the year to start a new venture.
BioNTech, the manufacturer of the Pfizer-BioNTech COVID-19 vaccine that is used in Singapore, set up its Tuas plant in 2021.
Leveraging cutting-edge manufacturing and digital infrastructure, the plant was envisioned to provide regional and global supply capacity for BioNTech’s products and allow it to respond quickly to address potential pandemic threats in the Southeast Asian region.
Continue reading...
The company has suffered losses in recent years and reported last month a net loss of €1.14 billion (US$1.31 billion) in 2025, compared with a €665 million loss in 2024.
“BioNTech made the strategic decision to close its planned Singapore site by the end of February 2027, as we continue to align capacity with our clinical portfolio and long-term strategic direction,” the COVID-19 vaccine maker told CNA.
“We recognise the significant contributions of our employees affected by these changes and are committed to supporting them through this transition.”
CNA Games
Show More Show Less
The company added that it currently employs 85 people at its Singapore site in Tuas.
BioNTech also told CNA that it is committed to becoming a global immunotherapy powerhouse with multiple approved products.
“While we continue to invest in executing our vision, we remain committed to cost-effective value generation,” said the company.
“We actively manage our whole pipeline and assess all sites across BioNTech, according to key criteria: strategic alignment, operational efficiency, and sustainable value creation.
“We consequently plan to continue to significantly invest in essential areas while optimising capacities in others.”
The impending closure of its Singapore plant comes shortly after BioNTech's two co-founders and leading executives, CEO Ugur Sahin and Chief Medical Officer Oezlem Tuereci, announced on Mar 10 that they will leave the vaccine maker before the end of the year to start a new venture.
BioNTech, the manufacturer of the Pfizer-BioNTech COVID-19 vaccine that is used in Singapore, set up its Tuas plant in 2021.
Leveraging cutting-edge manufacturing and digital infrastructure, the plant was envisioned to provide regional and global supply capacity for BioNTech’s products and allow it to respond quickly to address potential pandemic threats in the Southeast Asian region.
Continue reading...